Audit Information	12 Months Ended
Jun. 30, 2026
Auditor [Line Items]
Auditor Name	GRANT THORNTON AUDIT PTY LTD
Auditor Firm ID	2233
Auditor Location	Melbourne, Australia
Auditor Opinion [Text Block]	Opinion on the financial statements We have audited the accompanying consolidated statements of financial position of Radiopharm Theranostics Limited and subsidiaries (the “Group”) as of June 30, 2026 and 2025, the related consolidated statements of profit or loss and other comprehensive income, changes in equity, and cash flows for each of the three years in the period ended June 30, 2026, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Group as of June 30, 2026 and 2025, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2026, in conformity with International Financial Reporting Standards, as issued by the International Accounting Standards Board.

2233

Opinion on the financial statements

We have audited the accompanying consolidated statements of financial position of Radiopharm Theranostics Limited and subsidiaries (the “Group”) as of June 30, 2026 and 2025, the related consolidated statements of profit or loss and other comprehensive income, changes in equity, and cash flows for each of the three years in the period ended June 30, 2026, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Group as of June 30, 2026 and 2025, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2026, in conformity with International Financial Reporting Standards, as issued by the International Accounting Standards Board.